ArchiveImmunoglobulin A nephropathy(IgAN) is the primary glomerular disease that leads to end-stage renal disease(ESRD), 40% of IgAN patients have progressed to ESRD within 20 years after diagnosis, and it is a common cause of renal failure among young people in China. The current supportive treatment, corticosteroids, and non-specific immunosuppressants have limited effects. New therapies targeting the specific mechanisms of IgAN are urgently needed.This article reviewed the latest progress of hot drugs for IgAN immunotherapy, including B-cell-targeting drugs and complement-targeting drugs, focusing on related pharmacology, clinical research and safety, in order to provide references for research and application.
Immunoglobulin A nephropathy(IgAN) is the most prevalent primary glomerular disease worldwide.Traditional treatments have shown poor efficacy and are associated with numerous adverse reactions. Currently, the continuous emergence of non-immunosuppressive therapeutic drugs has broken the limitations of traditional single-mechanism approaches through multi-target intervention. This article systematically reviewed the pharmacological mechanisms, key clinical evidence, and clinical applications of three hot-spot non-immunosppressive therapeutic drugs such as endothelin receptor antagonists, sodium-dependent glucose transporters 2 inhibitors, and non-steroidal glucocorticoid receptor antagonists, in order to provide a reference for the clinical application.
To investigate the protective effect of Chaishao Liujunzi decoction on the gastric mucosal barrier in mice with liver-stomach disharmony type gastric ulcer(GU), as well as its influence on oxidative stress injury and the Kelch-like ECH-associated protein (Keap)1/nuclear factor erythroid 2-related factor(Nrf2)/heme oxygenase(HO)-1 signaling pathway.
Forty Kunming mice, half male and half female, were randomly divided into the blank control group, model group, omeprazole group, and Chaishao Liujunzi Decoction group, with 10 mice in each group. The liver-stomach disharmony type GU model was established by using the "emotional stimulation intervention method+intragastric administration of anhydrous ethanol method". After successful establishment of the model, the corresponding drugs were administered by gavage for 2 weeks. Hematoxylin-eosin staining was used to observe the pathological changes of the gastric mucosa. AB-PAS staining was employed to examine the distribution of mucopolysaccharides in the gastric mucosa. Scanning electron microscopy was used to observe the ultrastructural morphology of the gastric mucosa. The DHE fluorescence probe method was used to detect the level of reactive oxygen species(ROS), malondialdehyde(MDA),glutathione peroxidase(GSH-Px), superoxide dismutase(SOD), interleukin(IL)-6, tumor necrosis factor(TNF)-α in the gastric tissue. Immunofluorescence was performed to observe the positive expression of mucin(MUC)5AC and cyclooxygenase(COX)-2 proteins in the gastric mucosa. Immunoblotting was conducted to detect the relative expression of Keap1, Nrf2, HO-1, occludin, epithelial cadherin(E-cadherin), and MUC1 proteins in the gastric tissue.
Compared with the model group, both the omeprazole group and the Chaishao Liujunzi decoction group showed reduced pathological damage of gastric mucosa, increased mucopolysaccharide content, and alleviated ultrastructural damage. The levels of ROS, MDA, IL-6, and TNF-α decreased(P<0.01), the levels of SOD and GSH-Px increased(P<0.01), the average fluorescence intensity of MUC5AC and the relative expression levels of Nrf2, HO-1, and occludin proteins increased(P<0.01), and the average fluorescence intensity of COX-2 and the relative expression level of Keap1 decreased(P<0.01). Compared with the omeprazole group, the Chaishao Liujunzi Decoction group exhibited lower levels of SOD and GSH-Px and the expression level of Keap1(P<0.01), while the expression levels of Nrf2, HO-1, occludin,E-cadherin, MUC1 proteins and the average fluorescence intensity of MUC5AC increased(P<0.05).
Chaishao Liujunzi decoction can alleviate gastric mucosal pathology and ultrastructural damage, reduce ROS production and lipid peroxidation, enhance the activity of antioxidant enzymes, down-regulate the levels of inflammatory factors, and up-regulate the protein expressions of occludin, E-cadherin, MUC1 and MUC5AC to increase mucopolysaccharide content in liver-stomach disharmony type GU mice to protect gastric mucosal barrier. Its protective mechanism may be related to regulating the Keap1/Nrf2/HO-1 signaling pathway, thereby mediating antioxidant, anti-inflammatory and mucosal barrier repair. Moreover, Chaishao Liujunzi decoction is superior to omeprazole in some indicators.
To explore the clinical efficacy of DM120 decoction as an adjuvant treatment for diabetic nephropathy(DN) and its effects on transforming growth factor(TGF)-β1 and interleukin(IL)-6.
A total of 80 patients with DN admitted to the Endocrinology Department of our hospital were enrolled, and divided into the control group(standard treatment) and the treatment group(standard treatment+DM120 decoction) by simple random sorting method, with 40 cases in each group. The changes in renal function, urine protein, micro-inflammatory factors, and the traditional Chinese medicine(TCM) syndrome scores of Qi-yin deficiency combined with blood stasis syndrome before and after treatment were analyzed and compared between the two groups.
After treatment, the serum creatinine in the treatment group decreased compared with that before treatment(P<0.05), the glomerular filtration rate increased(P<0.05), and the urine protein indicators in both groups decreased compared with those before treatment(P<0.05). The improvement of these indicators in the treatment group was better than that in the control group at the same time point(P<0.05). The levels of serum and urine TGF-β1 and IL-6 in both groups decreased compared with those before treatment(P<0.05), with a greater reduction observed in the treatment group than in the control group(P<0.05). The efficacy scores of TCM syndromes such as dry throat, dry mouth, fatigue, overeating and hunger, shortness of breath, laziness of speech, five-centers restlessness, lower extremity edema, and limb pricking pain in the treatment group were higher than those in the control group(P<0.05).
DM120 decoction as an adjuvant treatment for DN has definite efficacy.It can relieve symptoms, protect renal function, reduce urine protein and blood urine TGF-β1 and IL-6 levels, improve micro-inflammatory state, and is worthy of promotion and application.
To explore the therapeutic effect of fenofibrate combined with dapagliflozin in the treatment of diabetic nephropathy(DN).
This study was a prospective randomized controlled trial. 500 patients with DN who admitted to the department of nephrology, Hebei hepatopathy hospital of traditional Chinese medicine from January 2021 to January 2024 were selected and randomly divided into the control group and the observation group, with 250 cases in each group. The control group was treated with dapagliflozin orally, while the observation group was treated with fenofibrate in addition to the treatment of the control group. Both groups were treated continuously for 12 months. The primary endpoint was the renal composite hard endpoint[defined as a declinein estimated glomerular filtration rate(eGFR)of ≥40% or progression to end-stage renal disease] at 12 months of treatment, and the secondary endpoints included differences in blood glucose indicators, renal function indicators, inflammatory factors, microcirculation indicators,oxidative stress indicators before treatment, at 6 and 12 months of treatment, as well as safety comparisons.
After 12 months of follow-up, the incidence of the renal composite hard endpoint in the observation group was lower than that in the control group(P<0.05). At 6 and 12 months, the fasting blood glucose, glycosylated hemoglobin, serum creatinine,24-hour urinary microprotein excretion rate, β2 microglobulin, C-reactive protein, interleukin-6, endothelin-1, fibrinogen,whole blood low shear viscosity, malondialdehyde in the observation group were lower than those in the control group,while the superoxide dismutase and glutathione peroxidase were higher than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).
Fenofibrate combined with dapagliflozin can significantly reduce the risk of the renal composite hard endpoint in patients with DN, demonstrating a clear long-term renal protective effect. It may achieve this through multiple pathways such as synergistically regulating blood glucose, protecting renal function, inhibiting the systemic inflammation, improving microcirculation, and reducing oxidative stress damage. Moreover, it does not increase adverse reactions, with good safety.
To explore the impact of anlotinib combined with toripalimab on the therapeutic efficacy and safety of patients with advanced non-small cell lung cancer(NSCLC).
A total of 88 patients with advanced NSCLC admitted to our hospital from March 2023 to June 2025 were selected. They were divided into the conventional group(anlotinib) and the combined group(anlotinib+teprotumumab) according to different treatment regimens. The objective response rate(ORR) and disease control rate(DCR) were compared between the two groups. The levels of serum indicators, tumor markers, quality of life and safety were evaluated between the two groups.
The ORR and DCR in the combined group(38.30% and 87.24%) were both higher than those of the conventional group(17.07% and 68.29%, P<0.05). Compared to before treatment, the levels of serum indicators and tumor markers in both groups were lower(P<0.05), and the combined groups was obviously lower than the conventional group(P<0.05). The scores of the functional assessment of cancer therapy-lung cancer(FACT-L) scale of the two groups increased compared to before, and the scores of the Patient Health Questionnaire-9(PHQ-9) decreased(P<0.05). Moreover, the FACT-L score of the combined group was higher than that of the conventional group, and the PHQ-9 score was lower than that of the conventional group(P<0.05). There was no significantly difference in the incidence of adverse reactions between the two groups(P>0.05).
The combination therapy of anlotinib and toripalimab can significantly reduce the levels of serum tumor markers in patients with advanced NSCLC, improve their quality of life, and has remarkable efficacy.Moreover, it demonstrates good safety.
To evaluate the therapeutic mechanism of mepolizumab in type 2 inflammatory bronchial asthma.
The clinical data of 102 patients with type 2 bronchial asthma who were treated in our hospital from March 2024 to January 2025 were collected retrospectively. They were grouped according to different treatment regimens. The control group treated with budesonide formoterol and oral glucocorticosteroid(OCS) prednisone, while the observation group received mepolizumab in addition to the control group. The conditions of both groups after 6 months of treatment were collected and compared, including asthma control test(ACT) score, OCS dosage, eosinophil(EOS) count,immunoglobulin(Ig)E, fractional exhaled nitric oxide(FeNO), forced vital capacity(FVC), forced expiratory volume in one second(FEV1), peak expiratory flow(PEF), total bronchial surface area(TA), lumen area(LA), and wall area of tube(WA), and the number of readmissions due to asthma exacerbation over a 12-month follow-up period.
After treatment, the ACT score and OCS dosage in the observation group decreased more significantly compared with the control group(P<0.05), while the EOS count, IgE, and FeNO were lower in the observation group than in the control group(P<0.05), and the FVC, FEV1/FVC, and PEF in the observation group were higher than those in the control group(P<0.05).The LA in the observation group was higher than that in the control group(P<0.05), and the WA was lower than that in the control group(P<0.05), the 12-month follow-up showed that the number of re-admissions due to asthma exacerbation in the observation group was less than those in the control group(P<0.05). The multivariate logistic regression analysis showed that baseline EOS and FeNO were independent predictors for evaluating treatment response based on the ACT scoring(P<0.05).
Mepolizumab helps control the condition of type 2 inflammatory bronchial asthma, reduces the dosage of OCS. The main mechanism of action is speculated to be targeting the blockade of type 2 inflammatory biomarkers and improving airway remodeling.
To analyze changes in coagulation function and risk factors before and after tigecycline administration, so as to promote the rational use and prevent the occurrence of severe adverse reactions.
Clinical data of 114 severe infection patients who met the inclusion and exclusion criteria and received tigecycline at the Fifth Affiliated Hospital of Xinjiang Medical University from June 2022 to July 2023 were collected. Patients were divided into the normal coagulation group and the coagulation dysfunction group based on coagulation indicators. Univariate and multivariate logistic regression analysis were performed on indicators such as liver and kidney function, blood routine examination, and coagulation function.
At 1—3 days after treatment, patients showed prolonged activated partial thromboplastin time(APTT). At 3—5 days after treatment, patients showed prolonged APTT, prothrombin time(PT),and international normalized ratio, and decreased fibrinogen, with similar results at 5—7 days after treatment. Univariate analysis showed abnormal aspartate aminotransferase and alanine aminotransferase(ALT) were associated with coagulation dysfunction. Multivariate logistic analysis identified abnormal ALT as an independent risk factor(odds ratio=3.92, P<0.05).
Tigecycline may induce coagulation dysfunction in severe infection patients, including prolonged APTT, PT, international normalized ratio and decreased fibrinogen. Liver dysfunction is associated with coagulation disorders, and abnormal ALT may be an independent risk factor.
To evaluate the effects of intravitreal injection of anti-vascular endothelial growth factor(VEGF)drugs on visual acuity, retinal structure, and morphological outcome of retinal pigment epithelial detachment(PED) in patients with neovascular age-related macular degeneration(nAMD)-related PED.
A total of 33 patients(33 eyes)with PED related to nAMD who were initially treated in our hospital from March 2021 to February 2024 were included for retrospective analysis. The patients received intravitreal injection of conbercept or aflibercept. All patients completed at least 6 months of follow-up. The changes in optical coherence tomography(OCT) parameters at baseline and 1, 2, 3,and 6 months after vitreous injection and the best corrected visual acuity(BCVA) at baseline and 6 months after vitreous injection were evaluated. The primary outcome measures were BCVA and PED height, the secondary outcome measures were subretinal fluid(SRF) and central subfield thickness(CST).
At 6 months, the mean BCVA of all patients improved significantly compared with baseline(P=0.001), with 66.67%(22/33) of eyes showing visual acuity improvement. The mean PED height decreased compared with baseline(P<0.001), and the mean CST decreased compared with baseline(P<0.001). Additionally, 81.82%(27/33) of eyes achieved dry macula. Patients were divided into two subgroups based on the injection medication. At the study endpoint, there were no significant differences between the two groups in BCVA(P>0.05), PED height(P>0.05), or number of treatment injections(P>0.05).
Intravitreal injection of anti-VEGF drugs significantly reduces PED height, improves visual acuity, and decreases SRF and CST in treatment-naïve patients with nAMD-related PED.
To explore the efficacy of ceftriaxone sodium combined with Jinhuang powder topical application in the treatment of acute mastitis and its influence on the expression of inflammatory factors.
A total of 105 puerperal primiparous women with acute mastitis from January 2023 to November 2024 were selected. They were randomly divided into the control group(treated with ceftriaxone sodium) and the observation group(treated with ceftriaxone sodium combined with topical application of Jinhuang powder), by a simple randomization method. The clinical efficacy, traditional Chinese medicine(TCM) syndrome scores and visual analogue scale(VAS) scores were compared between the two groups.
After treatment, the clinical efficacy, TCM syndrome score and VAS score of the observation group were better than those of the control group(P<0.05). The observation group showed significantly shorter time to normal body temperature and resolution of swelling and pain compared to the control group(P<0.05).After treatment, the levels of C-reactive protein and white blood cells in the observation group were lower than those in the control group(P<0.05). The levels of intercellular adhesion molecule-1, procalcitonin, and soluble myeloid cell triggering receptor-1 in the observation group were also lower than those in the control group(P<0.05).
The topical application of Jinhuang powder can improve the expression of inflammatory factors, pain degree and recovery speed in patients with puerperium mastitis.
To explore the efficacy of the modified Baizhu Shaoyao Powder combined with montmorillonite powder(MP) in treating postoperative diarrhea after colorectal cancer(CRC) surgery, and its effects on gastrointestinal function and gastrointestinal hormone levels.
A total of 90 CRC postoperative diarrhea patients diagnosed at the Nanchong Hospital of Beijing Anzhen Hospital affiliated to Capital Medical University from June 2022 to June 2024 were enrolled. They were randomly divided into two groups using a random number table method: the single drug group(MP)and the dual drug group(MP combined with modified Baizhu Shaoyao Powder), with 45 cases in each group. All were intervened for 7 weeks. The therapeutic effects, gastrointestinal functions, the scores of traditional Chinese medicine syndromes, gastrointestinal hormones, intestinal microecological flora, and nutritional status before and after treatment were compared between the two groups.
After treatment, the efficacy of the dual-drug group was superior to that of the single-drug group(95.56% vs. 77.78%, P<0.05). The recovery time of bowel sounds and the time of anal exhaust in the dual-drug group were shorter than those in the single-drug group(P<0.05). The primary and secondary symptom scores, levels of motilin and gastrin, the numbers of Escherichia coli and Enterococcus in both groups were all lower than those before treatment(P<0.05). The levels of transferrin and prealbumin, the numbers of Lactobacillus and Bifidobacterium in both groups were all higher than before treatment(P<0.05). Moreover, the differences before and after treatment in the dual-drug group were greater than those in the single-drug group(P<0.05).
The modified Baizhu Shaoyao Powder combined with MP in the treatment of post-CRC diarrhea can accelerate the recovery of gastrointestinal function, regulate the levels of gastrointestinal hormones and the intestinal microecology, and significantly improve the therapeutic effect.
To explore the clinical application of ursodeoxycholic acid combined with glutathione in the treatment of cholestatic liver disease(CLD) and its impact on liver fibrosis.
A total of 151 patients with CLD who were treated at Shanxi Fenyang Hospital from December 2021 to January 2024 were selected and divided into the control group(75 cases, treated with adenosine methionine combined with glutathione) and the observation group(76 cases,treated with ursodeoxycholic acid combined with glutathione). The clinical efficacy, liver fibrosis indicators, liver function, bile acid indicators, Child-Pugh classification changes, and adverse reactions were compared between the two groups.
After treatment, the total effective rate of the observation group was higher than that of the control group, with a significant difference(92.11% vs. 80.00%, P<0.05). After treatment, the levels of type III procollagen, laminin, type Ⅳ collagen, and hyaluronic acid in both groups were lower than those before treatment(P<0.05). The levels in the observation group were lower than those in the control group(P<0.05). The levels of total bilirubin, alanine aminotransferase, and aspartate aminotransferase in both groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group(P<0.05). The levels of bile acids and cholylglycine in both groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group(P<0.05). The Child-Pugh classification in both groups showed improvement and the improvement degree in the observation group was better than that in the control group(P<0.05). The adverse reactions were mainly nausea, vomiting, abdominal distension, liver pain, and decreased platelet count, but the differences were not statistically significant(P>0.05).
The combination of ursodeoxycholic acid and glutathione can exert a synergistic effect,effectively reverse the process of liver fibrosis, significantly improve liver synthesis and metabolism, and provide a better treatment option for CLD patients.
To investigate the effects of Bailing capsule as an adjuvant therapy on oxidative stress levels in follicular fluid and the oocyte quality in patients with polycystic ovary syndrome(PCOS).
A total of 98 PCOS patients admitted to Chongming hospital affiliated to Shanghai health medical university from February 2023 to January 2025 were selected and divided into the Bailing capsule group and the reference group by simple random sorting method,53 cases in each group. After attrition, the final analysis included 50 cases in the Bailing capsule group and 48 cases in the reference group. The reference group received subcutaneous injection of liraglutide on the first day of menstruation and oral administration of letrozole from D3 to D7. The Bailing capsule group received Bailing capsule as an adjuvant treatment from D5 of menstruation in addition to the treatment of the reference group. Both groups were treated for 3 menstrual cycles. The oocyte quality(number of fertilized oocytes, number of cleaved embryos, number of transplantable embryos, number of high-quality embryos), levels of oxidative stress in follicular fluid[reactive oxygen species(ROS),malondialdehyde(MDA), superoxide dismutase(SOD)], endocrine indicators[follicle-stimulating hormone(FSH),luteinizing hormone(LH), testosterone(T)], traditional Chinese medicine syndrome scores(menstrual irregularity, breast distension, dizziness and tinnitus, restlessness and discomfort) were compared between the two groups and the occurrence of adverse reactions was compared between the two groups.
After treatment, the number of fertilized oocytes,number of cleaved embryos, number of transplantable embryos, and number of high-quality embryos in the Bailing capsule group were higher than those in the reference group(P<0.05). After treatment, the levels of ROS and MDA in both groups were lower than those before treatment(P<0.05), and SOD increased(P<0.05). The improvement in the Bailing capsule group was more significant compared to the reference group(P<0.05). The levels of FSH, LH, and T in both groups were lower than those before treatment(P<0.05), and the improvement in the Bailing capsule group was more significant compared to the reference group(P<0.05). The scores of menstrual irregularity, breast distension, dizziness and tinnitus, and restlessness and discomfort in both groups were lower than those before treatment(P<0.05), and the improvement in the Bailing capsule group was more significant compared to the reference group(P<0.05). There was no significant difference in adverse reactions between the two groups(P>0.05).
Bailing capsule as an adjuvant therapy for PCOS can effectively improve the quality of oocytes in patients. Its underlying mechanism may be closely related to the improvement of the oxidative stress state of follicular fluid and the regulation of endocrine-related indicators.
To investigate the composition characteristics of urinary calculi and influencing factors of infectious stones in hospitalized patients in Bengbu and surrounding areas.
A total of 624 patients with urinary calculi from June 2022 to January 2025 in Bengbu and surrounding areas were retrospectively analyzed. The composition of stones was analyzed by infrared spectroscopy. Based on the clinical characteristics such as gender, age, and stone location of the patients, the independent risk factors of infectious stones were screened by logistic regression models.
Among the 624 patients with urinary calculi, ureteral stones were the main type(337 cases, 54.01%), followed by kidney stones(200 cases, 32.05%). The main component of the stones was calcium oxalate stones(242 cases, 38.78%).The proportion of female patients with infectious stones and calcium phosphate+carbonate apatite+mixed types was significantly lower than that in male patients(P<0.05), and the proportion of male patients with uric acid/urate stones was significantly higher than that in female patients(P<0.05). The multivariate logistic regression analysis showed that female gender[odds ratio(OR)=2.314, 95% confidence interval(CI): 1.286 - 4.167], history of diabetes(OR=3.826, 95%CI: 1.985 - 7.374), uric pH value≥7.0(OR=5.219, 95% CI: 2.897 - 9.406), staghorn calculi(OR=4.762,95%CI: 2.105 - 10.743), and positive urine culture(OR=6.385, 95%CI: 3.421 - 11.938) were independent risk factors for infectious stones(all P<0.05).
In the Beigang area and surrounding regions, the main types of urinary calculi are ureteral calculi and calcium oxalate stones. Female gender, history of diabetes, urine pH ≥ 7.0, staghorn calculi, and positive urine culture are independent risk factors for infectious stones. Targeted prevention and treatment strategies should be implemented clinically to reduce the recurrence rate.
To explore the therapeutic effect of umbilical moxibustion combined with Bifidobacterium quadruple viable tablets in the treatment of constipation in Parkinson's disease(PD).
A total of 72 patients with PD constipation admitted to our hospital from March 2023 to September 2024 were selected and randomly divided into the control group(recevied Bifidobacterium quadruple viable tablets) and the experimental group(received abdominal moxibustion combined with Bifidobacterium quadruple viable tablets). Each group consisted of 36 patients, and all were treated for 2 weeks. The clinical efficacy, traditional Chinese medicine syndrome scores, quality of life, severity of constipation, levels of gastrointestinal hormones, and safety between the two groups were compared.
After the treatment, the total effective rate of the experimental group was higher than that of the control group(P<0.05). The score reduction of the Chronic Constipation Severity Rating Scale in the experimental group was greater than that in the control group(P<0.05), and the reduction in traditional Chinese medicine syndrome scores was also greater in the experimental group than in the control group, but the difference was not statistically significant(P>0.05). The scores of the Quality of Life Scale for constipation patients and the PD quality of life questionnaire in the experimental group decreased more significantly than those in the control group(P<0.05). The levels of motilin and gastrin in the experimental group were higher than those in the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).
Umbilical moxibustion combined with Bifidobacterium quadruple viable tablets has a significant therapeutic effect on constipation in PD patients. It can effectively alleviate the severity of constipation, modulate gastrointestinal hormone levels, enhance quality of life metrics, and exhibits favorable safety profile.
Pulmonary fibrosis is a chronic progressive interstitial lung disease induced by multiple factors such as environmental exposure, infections. Its core pathological features are abnormal extracellular matrix deposition and myofibroblast over-activation. The efficacy of currently available therapeutic agents is limited, as they lack sufficient targeting capacity and are unable to reverse the progression of fibrosis. In recent years, pluripotent mesenchymal stem cells(MSCs) and their secreted extracellular vesicles(especially exosomes) have shown breakthrough potential in the treatment of pulmonary fibrosis due to their unique tissue repair and immunomodulatory functions. This article systematically reviewed the multidimensional antifibrotic mechanisms of MSCs and their extracellular vesicles(exosomes), deeply explored the engineered modification strategies(such as gene modification, novel vectors and delivery systems, and combined interventions) in enhancing therapeutic efficacy, and analyzed the challenges of translating from basic research to the clinic,in order to provide theoretical basis for the research of new anti-fibrosis drugs and the clinical application of MSCs.
Diabetic nephropathy(DN) is one of the common and serious chronic microvascular complications of diabetes mellitus. The pathogenesis of DN is complex, and podocyte injury plays an important role in the pathogenesis of DN. DN belongs to the category of "kidney deficiency""edema""guan ge" and other secondary symptoms of "thirst quenching disease" in traditional Chinese medicine. Qi deficiency and blood stasis run through the entire disease course.At present, there is a large amount of researches on the impact and safety of Western medicine and traditional Chinese medicine treatment on podocyte injury in DN. This article reviewed on the effects and possible mechanisms of Western medicine, traditional Chinese medicine compound, Chinese patent medicine and single traditional Chinese medicine on podocyte injury in DN, in order to provide ideas for the clinical diagnosis and treatment of podocyte injury in DN patients.
Diabetic peripheral neuropathy(DPN) is a common chronic complication of diabetes. In traditional Chinese medicine syndrome differentiation, DPN is divided into qi deficiency with blood stasis, qi and yin deficiency with blood stasis blocking the meridians, yang deficiency with cold congealing the collaterals, and yin and yang deficiency with blood stasis and obstruction of the meridians. The current research faces several bottlenecks, including the lack of objective molecular markers for syndrome diagnosis, inconsistent standards for compound preparation and application, and the disconnection between clinical and basic research. This article systematically reviewed the pathway regulation rules of traditional Chinese medicine compound intervention in DPN based on syndrome differentiation as the guiding framework.In the future, efforts should focus on the "syndrome- mechanism" correlation, clarify the molecular mechanism, establish a standardized system, and promote the transformation of traditional Chinese medicine treatment for DPN towards precision,standardization and modernization.
The zinc ion transporter LIV-1 protein (also known as SLC39A6, ZIP6) is localized on the cell membrane and contains multiple histidine-rich transmembrane domains. It participates in regulating the occurrence, development,invasion, metastasis, and epithelial-mesenchymal transition pathway of breast cancer, holding value as both a diagnostic marker and a potential therapeutic target in multiple cancers. With the breakthrough of antibody-drug conjugates in targeted therapy for breast cancer, the development and clinical application of LIV-1 protein-targeted drugs have become a new hotspot. This article reviews the research progress and therapeutic translational value of LIV-1 protein-targeted drugs in breast cancer and other malignancies from the perspectives of structure-activity relationship, pathological mechanisms,and tumor microenvironment regulation, aiming to provide a theoretical basis for innovating treatment strategies for related diseases.